This episode, titled Optimizing Subcutaneous Therapies in NSCLC: Practical Integration, Patient Selection, and Workflow ...

In the final episode, Overcoming Barriers and Future Integration of Subcutaneous Therapies in Lung Cancer, the panelists ...

A randomized trial finds weekly extended-release buprenorphine yields neonatal outcomes comparable to sublingual treatment.

The melanocortin 4 receptor agonist setmelanotide is now FDA approved for weight management in adults and children with ...

Forlong Biotechnology, a clinical-stage biotech company focusing on developing transformative cytokine therapies for patients with severe unmet needs, today announced that preclinical data from its IL ...

The European Investment Bank (EIB) has waived the put option attached to the warrants granted in connection with the €40 ...

Allergan Aesthetics, an AbbVie company, a global leader in medical aesthetics treatments and manufacturers of the market-leading JUVÉDERM® Collection of Fillers,3,4,‖ is once again forging ahead and ...

Chugai receives Japanese approval for Lunsumio & Polivy combo therapy for additional indication of relapsed or refractory large B-cell lymphoma: Tokyo Tuesday, March 24, 2026, 11: ...

Kali Therapeutics, a clinical-stage biotechnology company pioneering next-generation immune-resetting therapies, today ...

Closed Private Placement Financing of up to $30 Million HUNTSVILLE, March 25, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the "Company") (NYSE American: SER), a clinical-stage ...

Povetacicept significantly reduced proteinuria in patients with IgA nephropathy in the RAINIER trial, supporting an upcoming FDA submission.

According to Maximize Market Research, the Global Heparin Market is projected to reach USD 8.7 billion in 2025 and is expected to grow at a CAGR of 4.57% from 2026 to 2032. The market is witnessing ...